Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

A modulator of glucosylceramide degradation and pharmaceutical compositions containing the same. Also, the use of the modulator of glucosylceramide degradation and pharmaceutical compositions containing the same in the treatment or the prevention of viral infections and disorders associated to the viral infections, such as Zika infection, dengue infection, influenza infection and coronavirus infection.

The present invention relates to a homogeneous composition comprising a steroid compound and olopatadine, wherein the steroid compound is in a stable suspension state, and the olopatadine is in a stable solution state, and a process thereof.

The present invention relates to a homogeneous composition comprising a steroid compound and olopatadine, wherein the steroid compound is in a stable suspension state, and the olopatadine is in a stable solution state, and a process thereof.

Disclosed are methods for personalized treatment of tumor lesions in subject following primary tumor treatment. Disclosed are methods related to using patient specific prostate cancer dynamic model to adjust a patient's intermittent androgen deprivation therapy to determine when to pause IADT, when to resume IADT, the amount of treatment, and the rate of treatment and thereby increasing the time to progression of the tumor and thus prolonging post cancer treatment survival.

Disclosed are methods for personalized treatment of tumor lesions in subject following primary tumor treatment. Disclosed are methods related to using patient specific prostate cancer dynamic model to adjust a patient's intermittent androgen deprivation therapy to determine when to pause IADT, when to resume IADT, the amount of treatment, and the rate of treatment and thereby increasing the time to progression of the tumor and thus prolonging post cancer treatment survival.

The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs. The present invention also provides a method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1 or an inhibitor of ALK5, thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.

The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs. The present invention also provides a method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1 or an inhibitor of ALK5, thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.